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Introduction
Endometrial stromal sarcoma is a rare tumor of the
uterus and is even rarer outside of the uterus. It accounts
for 0.2% or less of all female genital tract malignancies
[1]. The majority of extrauterine endometrial stromal
sarcomas arise from endometriosis, which suggests a
process of malignant transformation [2]. Endometrial
stromal sarcomas with less than 10 mitotic figures
per 10 high powered fields (HPF) are classified as low
grade, and those with 10 or more/10 HPF are classified
as high grade [3]. Here, we present a case of low-grade
endometrial stromal sarcoma arising from endometrio-
sis, and managed by unilateral salpingo-oophorectomy
with ongoing high-dose progesterone therapy.
Case Report
A 28-year-old nulligravid woman with an unremarkable
medical history complained of progressive abdominal
distension accompanied by a palpable firm mass of
3 months’ duration. She first visited a local hospital
where abdominal computed tomography revealed a
large solid pelvic mass. She was transferred to our hos-
pital under the impression of ovarian malignancy. On
pelvic examination, the mass was found to be firm, non-
mobile, non-tender, and engaged at the cul-de-sac. The
complex septated mass measured 13 × 12 × 8 cm on
pelvic sonography, and had a heterogeneous pattern
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with high density, hypoechoic areas (Figure 1); there
was no obvious ascites. Pulsed Doppler examination
revealed low-resistance blood flow (resistance index,
0.33). CA125 level was elevated (348 U/mL). Chest
X-ray was negative.
The patient underwent exploratory laparotomy via
a vertical low abdominal incision. A left-side adnexal
mass about 12 cm in diameter was noted. It demon-
strated dense adhesion to surrounding organs, includ-
ing the uterine wall, retroperitoneum, and sigmoid co-
lon. The tumor consisted of flesh-like tissue mixed with
tumor hemorrhage. The right ovary was slightly enlarged
but grossly normal. The uterus was also slightly enlarged
to about 2 months’ gestation. A small amount of ascites
(50 mL) was noted. The viscera including the liver, small
and large intestines, peritoneum, mesocolon, mesentery,
and omentum were all grossly free of tumor involvement.
A frozen section examination of the tumor indicated
that it was benign, so the patient received a left-sided
salpingo-oophorectomy. The pathology of the tumor,
however, was extrauterine low-grade endometrial
stromal sarcoma with extensive endometrioid glandular
differentiation arising from endometriosis. Vascular
tumor emboli were seen and the resection margin was
involved (Figure 2). The mitotic activity in the spindle
cells in the most cellular area was about 2/10 HPF.
Both the spindle cell part and glandular part expressed
estrogen and progesterone receptors. Ascites cytology
tested negative for malignant cells. The patient has been
receiving high-dose progesterone therapy for 2 months
(medroxyprogesterone 500 mg/day) without any adverse
effects, except for an increase in body weight of 2 kg.
Discussion
Endometriosis is one of the most common benign gyne-
cologic conditions and has been estimated to affect
Figure 2. (A) Extensive endometrioid glandular differentiation arising from endometriosis (immunohistochemical [IHC] stain,
original magnification × 200). (B) Vascular tumor emboli were seen in the vessels (arrow) (IHC stain, original magnification
× 100).
Figure 1. (A) Transvaginal sonography and (B) abdominal sonography of the left adnexa shows a heterogeneous and complex
septated mass, measuring about 13 × 12 × 8 cm, with low impedance flow (resistance index, 0.33).
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approximately 10–25% of women presenting with gyne-
cologic symptoms in the United States. Malignant
transformation is a rare but well-documented compli-
cation of endometriosis, occurring in 0.7–1% of cases
[4]. The most common malignant transformation of
endometriosis is endometrioid carcinoma and clear cell
carcinoma followed by mucinous and serous carcinoma
[5]. Endometrial stromal sarcoma is rare. Endometrial
stromal neoplasms are divided into three groups:
endometrial stromal nodules, low-grade endometrial
stromal sarcomas, and high-grade endometrial stromal
sarcomas [3,6]. Endometrial stromal sarcoma is a rare
mesenchymal neoplasm that usually occurs as a primary
tumor of the uterus. However, endometrial stromal
sarcomas occasionally arise in other sites, such as the
ovary, fallopian tube, pelvic cavity, abdominal cavity,
and retroperitoneum [7]. Low-grade endometrial stro-
mal sarcomas, also known as endolymphatic stromal
myosis, are usually indolent tumors with excellent
prognoses. Recurrences and deaths can be delayed,
sometimes occurring more than 25 years after the
initial diagnosis [2].
To date, the pathogenesis of extrauterine endometri-
al stromal sarcoma remains controversial. The presence
of concomitant endometriosis is reported in about two-
thirds of cases. Its presence suggests that the stroma of
the ectopic endometrium is most likely to be the source
of the tumor [8]. Low-grade endometrial stromal sar-
comas of the ovary are among the rarest malignant
lesions of the female genital tract, with less than 50
cases presented in the literature [2]. The treatment of
disseminated endometrial stromal sarcoma arising from
endometriosis is problematic because of the rarity of
these tumors. Since the lesion is slow growing and well
differentiated, it typically has an indolent clinical course,
as with its counterpart in the uterus [8]. The overall
survival rate is significantly higher in patients with
endometrioid stromal sarcoma (70%) than in patients
with carcinosarcoma (45%) and leiomyosarcoma (19%)
[9]. Patients with untreated residual disease may be
free of signs or symptoms for many years [10]. For
example, four patients with disseminated low-grade
endometrioid stromal sarcoma of the ovary who had
residual disease after surgery were clinically free of
tumor without receiving adjuvant therapy 3, 5, 6 and
24 years later, respectively [8].
Surgical resection is the primary therapeutic ap-
proach. When the patient is perimenopausal or post-
menopausal, a hysterectomy with bilateral salpingo-
oophorectomy is the primary treatment of choice. But
a similar approach should also be considered for young
women [3]. Adjuvant therapy with radiotherapy,
chemotherapy, or progesterone therapy should be con-
sidered for the management of residual or recurrent
low-grade endometrial stromal sarcomas [8]. The effects
of radiation on endometrial stromal sarcomas are
equivocal [1]. The efficacy of adjuvant chemotherapy,
including either doxorubicin or vincristine plus actino-
mycin D or cyclophosphamide, is not established [11,
12]. Progesterone may be useful because good results
have been obtained in several series and case reports
[12]. The patient in this report was a 28-year-old nulli-
gravid woman who wanted to preserve her fertility. Af-
ter surgery, high-dose progesterone therapy was our
choice for adjuvant treatment. Since the treatment
strategy and clinical course of disseminated endometrial
stromal sarcoma arising from endometriosis have rarely
been reported, the follow-up of such cases should be
carefully carried out with regular pelvic examinations,
imaging studies, and tumor markers.
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